同位素2024，Vol.37Issue(2)：185-194,10.DOI:10.7538/tws.2023.youxian.067
无载体镥-177分离技术研究进展
No-Carrier-Added Lutetium-177 Separation Technology Status
李波 1胡映江 1吴建荣 1王磊 1陈云明 1张劲松 1罗宁1
作者信息
- 1. 中国核动力研究设计院,成都 610213||同位素及药物国家工程研究中心,成都 610213||四川省放射性同位素工程技术研究中心,成都 610213
- 折叠
摘要
Abstract
Medical isotopes are the substantial basis of the diagnostic and therapeutic nuclear medicine.There are irreplaceable advantages for utilizing the nuclear medical technology to diagnose and treat the malignant tumors,cardiovascular and cerebrovascular diseases,neurodegenerative diseases and other major diseases.Lutetium-177(177Lu)has excellent nuclear physical and chemical properties.In recent years,177Lu has been widely used in the research and clinical application of targeted nuclide therapy in the western developed countries,and the radio-labeled compounds have showed the good effects in the diagnosis and treatment of tumors,including neuroendocrine tumors,prostate cancer,metastatic disease in bone and etc.177Lu has been recognized as one of the most promising and dynamic economical theranostic targeted medical radio-isotopesand the global demand for 177Lu can be expected to grow explosively in the future.In this text,the preparation principle of 177Lu and current research status of 177Lu separation technology domestically or internationally,the future market demand and the application prospect were briefly introduced.关键词
中子辐照/有载体177Lu/无载体177Lu/放化分离/靶向放射性核素治疗Key words
neutron irradiation/carrier-added(CA)177Lu/no-carrier-added 177Lu/radiochemical separation/targeted radionuclide therapy分类
能源科技引用本文复制引用
李波,胡映江,吴建荣,王磊,陈云明,张劲松,罗宁..无载体镥-177分离技术研究进展[J].同位素,2024,37(2):185-194,10.
